We are delighted to welcome Dr. Barbato to Incannex as our Chief Medical Officer. With an established track record in directing drug development through late-stage clinical trials and multiple product ...

AbbVie has returned to the source of its antipsychotic powerhouse Vraylar in search of another blockbuster, paying $25 ...

He joins Incannex as the company continues to advance its lead clinical-stage programs in obstructive sleep apnea, generalized anxiety disorder, and rheumatoid arthritis. "We are delighted to welcome ...

A Duloxetine recall by the FDA has flagged more than 7,100 bottles of the Cymbalta generic drug due to a cancerous chemical.

AbbVie (ABBV) and Gedeon Richter announced a new discovery, co-development and license agreement to advance novel targets for the potential ...

AbbVie (NYSE: ABBV) and Gedeon Richter Plc. ('Richter') today announced a new discovery, co-development and license agreement to advance novel targets for the potential treatment of neuropsychiatric ...

N-nitroso-duloxetine belongs to the nitrosamine class of compounds, some of which are classified as probable or possible human carcinogens.

A gangster has been ordered by the B.C. Appeal Court to stand trial for a second time in the shooting deaths of a Cranbrook ...

A recent observational study published in the Journal of Pain & Palliative Care Pharmacotherapy suggests that patients with ...

The Company is investigating novel molecules within the CYB005 program at non-hallucinogenic doses for a range of Central Nervous System (“CNS”) disorders. In addition, the Company is continuing to ...

Anxiety and depression are more common among people with Crohn’s disease, and they can worsen symptoms. Here’s why and ways ...